URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>
Posts Tagged ‘androgen-deprivation therapy’
Acupuncture stops hot flashes in men having hormone treatment for prostate cancer
Posted in Hot flashes, tagged acupuncture, androgen ablation therapy, androgen-deprivation therapy, cancer research, catheter, Hormone therapy, hormone treatment, hot flashes, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, URO TODAY on July 31, 2010| Leave a Comment »
URO TODAY: Acupuncture provides excellent control of hot flashes in men undergoing androgen ablation therapy (hormone treatment) for prostate cancer, according to US researchers. READ MORE>
Testosterone slow to return after years of hormone therapy for prostate cancer
Posted in Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, tagged advanced prostate cancer, androgen-deprivation therapy, cancer research, catheter, Hormone therapy, long-term androgen deprivation therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, recovery of testosterone, URO TODAY on June 12, 2010| Leave a Comment »
URO TODAY: The recovery of testosterone after long-term androgen deprivation therapy for prostate cancer is slow, according to a study of about 20 patients who had been receiving hormone drugs for a mean seven years. READ MORE>
Fracture-reducing drug for prostate cancer patients also cuts down hormone therapy hot flushes
Posted in Bone loss, Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, androgen-deprivation therapy, cancer research, fracture-reducing drug, Hormone therapy, hot flashes, hot flushes, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, quality of life, toremifene, URO TODAY on October 18, 2009| Leave a Comment »
URO TODAY: A fracture-reducing drug called toremifene has a useful side effect when used on prostate cancer patients – it significantly reduces hot flushes caused by hormone therapy. READ MORE>
New prostate cancer drugs give hope of further life beyond chemotherapy
Posted in Hormone-refactory, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged abiraterone, advanced prostate cancer, androgen biosynthesis, androgen-deprivation therapy, beyond chemotherapy, cancer research, castrate-resistant prostate cancer, Chemotherapy, Hormone therapy, MDV3100, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, URO TODAY on October 8, 2009| Leave a Comment »
URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life. READ MORE>
NEW FIND: Prostate cancer may be caused by high-dose testosterone leaking from testes to prostate
Posted in PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, PSA tests, Testosterone treatment, Treatment news, Uncategorized, tagged androgen-deprivation therapy, cancer research, cause of prostate cancer, decrease in prostate volume, disappearance of cancerous cells, Hormone therapy, interventional radiological procedure, Israel, Maynei Hayeshua medical center, medical scientists in Israel, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, PSA, PSA test, Radiotherapy, Rehovot, repeat biopsies, super-selective intraprostatic androgen deprivation therapy, testicular and prostate venous (blood) drainage systems, testosterone leaks, URO TODAY, very highly concentrated testosterone, Weizmann Institute of Science on October 6, 2009| Leave a Comment »
URO TODAY: It’s very early days, but medical scientists in Israel may have made a new discovery about the cause of prostate cancer and subsequently how to treat it. READ MORE>
They believe that as men age, very highly concentrated testosterone leaks to the prostate gland via the testicular and prostate venous (blood) drainage systems.
They tried treating six men with an “interventional radiological procedure and super-selective intraprostatic androgen deprivation therapy” and in five cases achieved a decrease in prostate size and in PSA levels, with repeat biopsies showing disappearance of cancerous cells.
The work is being done at Maynei Hayeshua medical center and Department of Condensed Matter Physics, Weizmann Institute of Science, Rehovot, Israel.
At NEW PROSTATE CANCER INFOLINK, Mike Scott writes:
This is clearly a radical new finding that needs to be confirmed by other research groups.
Should it prove to be accurate, we may have a whole new mechanism available to treat early stage disease without having to expose patients to systemic forms of hormone therapy.
The “New” Prostate Cancer InfoLink emphasizes, however, that we have seen only an abstract of this report, and we need greater detail to understand what is actually being suggested by Gat and colleagues. READ MORE>
False balls that release bone-loss drugs may make testicle removal viable option again
Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, androgen-deprivation therapy, Bone loss, cancer research, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, slow-release drugs, testes removal, testicular prostheses, testosterone control, URO TODAY on September 15, 2009| Leave a Comment »
URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>
Low – not high – levels of testosterone may be new culprit in prostate cancer
Posted in Diagnosis, Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, Testosterone treatment, Treatment debate, tagged advanced stage of presentation, androgen-deprivation therapy, cancer research, high Gleason score, high serum testosterone, Hormone therapy, increased risk of biochemical recurrence after surgery, low serum testosterone, new testosterone evidence, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, testosterone, testosterone levels, URO TODAY, worrisome cancer features on September 6, 2009| Leave a Comment »
URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>
Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.
The older you are with high-risk prostate cancer, the better the outlook
Posted in Age factors, Hormone therapy, Hormone-refactory, tagged advanced prostate cancer, age factor, androgen-deprivation therapy, cancer research, castrate-resistant disease, clinical trials, Hormone therapy, older prostate cancer patients, prognosis, prognostic variables, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate treatment, secondary treatments, URO TODAY, worse prognosis, younger prostate cancer patients on September 4, 2009| Leave a Comment »
URO TODAY: Younger men with high-risk prostate cancer appear to have worse prognosis than older men with similar disease, according to a study of 4000 men receiving hormone treatment. READ MORE>
This, along with the other prognostic variables established in the current study, may help identify candidates for clinical trials evaluating secondary treatments for patients with castrate-resistant disease.
Study looks at ways new drugs suppress enzymes that feed advanced prostate cancer
Posted in Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Treatment debate, tagged 5AR, 5AR1 and 5AR2, 5AR2 monotherapy with finasteride alone, advanced prostate cancer, aggressive cancer growth, androgen receptor antagonist, androgen-deprivation therapy, asymptomatic, cancer research, comparison of treatments, dihydrotestosterone (DHT), enzymes, inhibition of 5alpha-reductase, intracellular androgen, isoenzymes, locally advanced or recurrent prostate cancer, pharmacological properties, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, therapeutic hormonal approach, tumour progression, URO TODAY on August 22, 2009| Leave a Comment »
URO TODAY: Enzymes in the prostate that promote aggressive cancer growth need to be suppressed and a study looks at the success of new drugs now available to do the job. READ MORE>
The objective of this review is to provide an understanding of the pharmacological properties and the potential clinical benefits of 5AR inhibition.
The efficacy of 5AR2 monotherapy with finasteride alone or in combination with an androgen receptor antagonist on more final outcome measures seems to be limited.
Combining an androgen receptor antagonist with a 5AR inhibitor in patients with asymptomatic, locally advanced or recurrent prostate cancer might be a reasonable first therapeutic hormonal approach.
5-alpha reductase is an enzyme that converts testosterone, the male sex hormone, into the more potent dihydrotestosterone:
